SolasCure enrols first patient in a next phase II clinical trial to advance Aurase Wound Gel

FHS
March 17, 2025
11:36 am

SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the initiation of a new Phase II clinical trial, CLEANVLU2.

Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases – Biotech Investments

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases 22.01.2025 / 07:30 CET/CEST

January 23, 2025

Caring for young caregivers, a hidden population

The intersection of the mental health crisis among young Americans and the growing burden of unpaid caregiving is generating an expanding, particularly vulnerable, and unacknowledged

May 9, 2024

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink | Psychedelic Invest

Vancouver, Canada, June 11, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and

June 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.